April 4 (Reuters) - Atara Biotherapeutics Inc ATRA.O:
ATARA BIOTHERAPEUTICS INC - ON MARCH 31, ENTERED AMENDMENT TO COMMERCIALIZATION AGREEMENT WITH PIERRE FABRE - SEC FILING
ATARA BIOTHERAPEUTICS INC - BIO TO RECEIVE UP TO $550 MILLION IN MILESTONE PAYMENTS - SEC FILING
ATARA BIOTHERAPEUTICS INC - PIERRE FABRE TO ASSUME COSTS FOR FDA REMEDIATION TO SUPPORT BLA RESUBMISSION FOR TAB-CEL - SEC FILING
Source text: [ID:n0000950170-25-051121]
Further company coverage: ATRA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.